A schematic representation of cancer-specific alternative gene splicing.

<p>(a) Brain cancer (gene ACYl), (b) breast cancer (SRP19), (c) liver cancer (CDK5), (d) lung cancer (CDKN1A), and (e) prostate cancer (SMS). Cancer-specific isoforms are showed on the bottom in each panel. The biological processes of these transcripts (GO process) are indicated on the right. Deleted domains are shown with blue arrows. Arrows with a right angle indicate the start codon, ATG.</p

Percentages of the types of alternative splice sites.

<p>The splice sites include GT-AG, GC-AG, GG-AG, GT-GG, and the others (a) in human cancer (b) and normal tissues. (c) Percentage distribution of the splice sites in five types of cancer and normal tissues (brain, breast, lung, liver, and prostate).</p

Oncogenes and tumor suppressors with cancer-specific AS events.

<p>Oncogenes and tumor suppressors with cancer-specific AS events.</p

Numbers of libraries and ESTs in normal tissues.

<p>Numbers of libraries and ESTs in normal tissues.</p

The frequencies (percentages) of the five types of cancer- and normal tissue-specific alternative splicing.

<p>(a) 16 types of human cancer and 17 normal tissues, (b) the average values between tumors and normal tissues. The five colors indicate the five types of tissue-specific alternative splicing: cassette alternative exon, alternative 5′ splice site, alternative 3′ splice site, intron retention, and mutually exclusive alternative exons. Yellowish regions indicate over 30% of the frequencies.</p

Numbers of cancer-specific AS transcripts and their genes.

<p>Numbers of cancer-specific AS transcripts and their genes.</p

Numbers of normal tissue-specific AS transcripts and their genes.

<p>Numbers of normal tissue-specific AS transcripts and their genes.</p

Biological processes of alternatively spliced transcripts specific to cancer.

<p>The five cancer types are brain, breast, liver, lung, and prostate cancer. The numbers indicate the percentages for each process in the cancer. The GO process classification is based on the PANTHER (<a href="http://www.pantherdb.org/tools/genexAnalysis.jsp" target="_blank">http://www.pantherdb.org/tools/genexAnalysis.jsp</a>).</p

A schematic representation of cancer-specific alternative gene splicing.

<p>(a) Oncogene, (b) tumor suppressor gene. The alternative splicing of RAF1 generates a lung cancer-specific transcript, whereas the alternative splicing of FOS produces an uterus cancer-specific transcript. Tumor suppressor GLTSCR2 is alternatively spliced to produce two retinoblastoma-specific transcripts and EMP3 to generate a skin cancer-specific transcript. Deleted domains are shown with blue arrows. Arrows with a right angle indicate the start codon, ATG.</p

Numbers of libraries and ESTs in cancers.

<p>Numbers of libraries and ESTs in cancers.</p